Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Apexigen has entered into a collaboration and worldwide license agreement with Centocor Research & Development and its affiliates to utilise Apexigen's proprietary therapeutic antibody technologies to discover and develop monoclonal antibody drugs.
Subscribe to our email newsletter
Apexigen will generate and screen antibodies to several targets specified by Centocor R&D, which will be responsible for development and commercialization of all products resulting from the collaboration.
Apexigen will receive an upfront license fee, and is eligible to receive future milestone and royalty payments if certain development and commercialisation milestones are achieved.
Apexigen president & CEO Xiaodong Yang said that they are excited about this collaboration and look forward to working closely with Centocor R&D.